Source – naturalnews.com
– “…The success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines …Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise”
SM:…You just can’t make this s#@t up…
Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.
“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise”
The analyst didn’t immediately respond to a request for comment.
The report suggested three potential solutions for biotech firms:
“Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually.”
“Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe.”
“Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets.”
Vaccines found to be deliberately formulated with hundreds of cancer genes to ensure repeat business for Big Pharma – By Ethan Huff
Groundbreaking research out of Italy has uncovered shocking new details about the aborted human fetal cell lines that are used in many of today’s childhood vaccines.
As reported by Children’s Health Defense (CHD), a group known as Corvelva discovered that the original MRC-5 aborted baby cell line from which vaccines are still made today is derived from the entire human genome of an aborted male baby with “abnormal” genes.
As it turns out, some 560 of these abnormal genes have been linked to cancer, suggesting that a person’s cancer risk increases every time he or she is injected with yet another vaccine that contains this tainted MRC-5 aborted baby cell line.
In case you’re unfamiliar with MRC-5, this cell line is still being used in vaccines like the MMRV, which is manufactured by GlaxoSmithKline (GSK), as well as in Twinrix (for Hepatitis A and B), Proquad (another MMRV vaccine), and Varivax (for varicella and chicken pox).
While it was already known that this MRC-5 cell line came from aborted fetal tissue, what was not known is that it came from a single male baby – and with some serious health problems, no less.
“The fetal human DNA represented in this vaccine is a complete individual genome, that is, the genomic DNA of all the chromosomes of an individual is present in the vaccine,” CHD explains about this new revelation.
“The human genomic DNA contained in this vaccine is clearly, undoubtedly abnormal, presenting important inconsistencies with a typical human genome, that is, with that of a healthy individual.”
Discover how to prevent and reverse heart disease (and other cardio related events) with this free ebook: Written by popular Natural News writer Vicki Batt, this book includes everything you need to know about preventing heart disease, reversing hypertension, and nurturing your cardiac health without medication. Learn More.
The public health consequences of MRC-5’s cancer-causing genes remains unknown
As for the 560 cancer-causing genes in MRC-5, the Corvelva research team found that these also have many variations for which the consequences remain unknown, “not yet appearing in the literature, but which still affect genes involved in the induction of human cancer,” CHP reveals.
In other words, nobody knows how these genetic variations are affecting people because they’ve apparently never been studied – and yet, we’re all supposed to believe that all vaccines are 100 percent safe and effective?
MRC-5 isn’t the only aborted fetal cell line in vaccines that’s problematic, either. According to Corvelva’s inquiry, WI-38, another aborted fetal cell line, is similarly problematic. And both MRC-5 and WI-38, it turns out, have no upper limits when it comes to the amount of them that are allowed in vaccine material.
Since the time when MRC-5 and WI-38 first started being used in vaccines around the 1960s, testing protocols have changed. But the reference literature for their use hasn’t been updated for about 40 years, until now.
Using Next NGS methodology in its metagenomic analysis, Corvelva compiled the data that drug companies and the federal government should have already compiled years ago, especially before deciding to add increasingly more vaccines to the official schedule.
So what does this all mean in practical terms? It means that vaccines today contain potentially tumorigenic materials that could cause people who receive them to develop cancer. Not only that, but the safety guidelines that correspond with these vaccines are woefully outdated and entirely inadequate in light of this revelation.
“What’s clear from this genetic sequencing is that the vaccine industry is inoculating children with engineered cancer,” contends Mike Adams, the Health Ranger.
“As CHD explains, the vaccines are deliberately formulated with cancer-causing genes which have been specifically modified to promote cancer tumors … Not only is this cancer-ridden genetic code inserted into all these vaccines given to children, but the dose of the cancer-infected DNA is dangerously high.”